Company Description

Basking Biosciences' lead candidate, BB-031, is being evaluated in an ongoing Phase II clinical trial in patients with acute ischemic stroke. The investigational RNA aptamer targets von Willebrand Factor (vWF) to promote clot dissolution and restore blood flow to the brain.